Login Get Started
Browse
Shares
Healthcare
Biotechnology & Medical Research
Zogenix Inc
Zogenix Inc logo

ZGNX - Zogenix Inc Share News

$32.18 -0.1  -0.2%

Last Trade - 14/02/20

Sector
Healthcare
RiskRating
Speculative
Size
Mid Cap
Style
Sucker Stock
Market Cap £1.09bn
Enterprise Value £896.2m
Revenue £1.30m
Position in Universe 2158th / 6403
Quality
Value
Momentum
StockRank™
StockReport™
Tools
Compare with... Run through checklist
Accounts
Balance sheet Income statement Cashflow statement Dividend summary
Charts News Discussions ZGNX Dividends
All News
All News Reuters News Company Announcements
BRIEF-Zogenix Inc Disclosed Estimated, Unaudited Cash, Cash Equivalents & Marketable Securities As Of Dec 31, Were $251.2 Mln
Thu 10:35pm News
BUZZ-U.S. STOCKS ON THE MOVE-Uber, Abbvie, Gilead, Tesla, Skechers, Ford
7th Feb News
BUZZ-U.S. STOCKS ON THE MOVE-AbbVie, Tesla, Uber, Skechers, Ford, eBay
7th Feb News
BUZZ-Zogenix: Falls as epilepsy drug data underwhelms; analysts still see approval
7th Feb News
BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Uber, Skechers, Take-Two, eBay
7th Feb News
BUZZ-Zogenix: Latest epilepsy drug data underwhelms, approval still seen- analysts
7th Feb News
CORRECTED-BUZZ-Zogenix: Plunges as rare epilepsy drug fails secondary goal in late-stage study
6th Feb News
BRIEF-Zogenix Announces Positive Top-Line Results From Global Pivotal Phase 3 Trial Of Fintepla
6th Feb News
Zogenix Announces Positive Top-line Results from Global Pivotal Phase 3 Trial of FINTEPLA® for the Treatment of Lennox-Gastaut Syndrome
6th Feb News
BRIEF-The Lancet Publishes Phase 3 Trial Results For Zogenix Investigational Drug Fintepla
18th Dec '19 News
The Lancet Publishes Phase 3 Trial Results for Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome
18th Dec '19 News
Zogenix to Host Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2019 Annual Meeting
5th Dec '19 News
BRIEF-Zogenix Inc - Announced Jama Neurology Has Published Results Of Zogenix's Phase 3 Study (Study 1504) Of Investigational Drug, Fintepla
2nd Dec '19 News
JAMA Neurology Publishes Phase 3 Study of Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome Patients Taking Stiripentol-Containing Antiepileptic Drug Regimens
2nd Dec '19 News
Zogenix to Present New Data for Its Investigational Drug FINTEPLA® at the American Epilepsy Society Annual Meeting
2nd Dec '19 News
Zogenix to Participate in the 31st Annual Piper Jaffray Healthcare Conference
27th Nov '19 News
BRIEF-Zogenix Announces FDA Acceptance For Filing Of New Drug Application And Priority Review For Fintepla For The Treatment Of Dravet Syndrome
25th Nov '19 News
BUZZ-Zogenix rides higher as FDA accepts application for seizure drug
25th Nov '19 News
Zogenix Announces FDA Acceptance for Filing of New Drug Application and Priority Review for FINTEPLA® for the Treatment of Dravet Syndrome
25th Nov '19 News
Zogenix to Present at Two Investor Conferences in November
12th Nov '19 News
© Stockopedia 2020, Refinitiv, Share Data Services.
Youtube Instagram RSS
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.